Drug recall · November 22, 2017
Meclizine hydrochloride tablets USP recall
Why: Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06
- Lots / codes
Lot # 17P0430, Exp 05/19
- Quantity
- 744 bottles
- Company
- Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD
- Distribution
- Nationwide
- Initiated
- October 30, 2017 · Voluntary: Firm initiated
- Classified
- November 16, 2017
- Reported
- November 22, 2017
- Ended
- February 12, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Meclizine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.